Ablatherm® - HIFU EDAP TMS currently develops and markets, through its subsidiary EDAP SA, devices for the minimally invasive destruction of certain types of localized tumors using HIFU technology. HIFU technology is intended to allow the surgeon to destroy a well-defined area of diseased tissue without damaging surrounding tissue and organs, thereby eliminating the need for incisions, transfusions, general anesthesia and their resulting complications.

The Ablatherm®, a HIFU-based device developed and manufactured by the Company for the treatment of organ-confined prostate cancer, is approved for commercial distribution in the European Union, Canada, South Korea and Russia.

For more information on Ablatherm® - Hifu, please visit www.edap-hifu.com

Shockwaves Lithotripsy (SWL) - Sonolith

The Company also produces and markets, through its subsidiary TMS SA, devices for the treatment of urinary tract stones using ESWL technology. ESWL lithotripters, which are widely used for the minimally-invasive treatment of urinary tract calculous disease, are designed to fragment urinary stones within the human body, thereby permitting their natural elimination.
The Company currently manufactures two models of lithotripters: • The SONOLITH Praktis, which is available for commercial distribution in the European Union, Japan, the United States, Canada and South Korea. • The SONOLITH Vision, which is available for commercial distribution in the European Union, Canada, Japan and South Korea. For more information on SWL - Sonolith, please visit www.tms-uro.com